CA3088754A1 - Methods for colon cancer detection and treatment monitoring - Google Patents
Methods for colon cancer detection and treatment monitoring Download PDFInfo
- Publication number
- CA3088754A1 CA3088754A1 CA3088754A CA3088754A CA3088754A1 CA 3088754 A1 CA3088754 A1 CA 3088754A1 CA 3088754 A CA3088754 A CA 3088754A CA 3088754 A CA3088754 A CA 3088754A CA 3088754 A1 CA3088754 A1 CA 3088754A1
- Authority
- CA
- Canada
- Prior art keywords
- score
- expression level
- subject
- therapy
- pdxk
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Evolutionary Biology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioethics (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862620015P | 2018-01-22 | 2018-01-22 | |
| US62/620,015 | 2018-01-22 | ||
| PCT/US2019/014490 WO2019144099A1 (en) | 2018-01-22 | 2019-01-22 | Methods for colon cancer detection and treatment monitoring |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3088754A1 true CA3088754A1 (en) | 2019-07-25 |
Family
ID=65279827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3088754A Pending CA3088754A1 (en) | 2018-01-22 | 2019-01-22 | Methods for colon cancer detection and treatment monitoring |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11414707B2 (https=) |
| EP (1) | EP3743534B1 (https=) |
| JP (1) | JP7297770B2 (https=) |
| KR (1) | KR20200113237A (https=) |
| CN (1) | CN112004945B (https=) |
| AU (1) | AU2019209436B2 (https=) |
| BR (1) | BR112020014737A2 (https=) |
| CA (1) | CA3088754A1 (https=) |
| DK (1) | DK3743534T3 (https=) |
| ES (1) | ES2917629T3 (https=) |
| IL (1) | IL276089B2 (https=) |
| MX (1) | MX2020007771A (https=) |
| PL (1) | PL3743534T3 (https=) |
| SG (1) | SG11202006974WA (https=) |
| WO (1) | WO2019144099A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3743534T3 (pl) | 2018-01-22 | 2022-09-05 | Liquid Biopsy Research LLC | Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia |
| MX2022004372A (es) | 2019-10-10 | 2022-07-27 | Liquid Biopsy Res Llc | Composiciones, métodos y kits para la estabilización de muestras biológicas y de arn. |
| US11809379B2 (en) * | 2019-11-19 | 2023-11-07 | International Business Machines Corporation | Storage tiering for deduplicated storage environments |
| CN111157745A (zh) * | 2020-01-17 | 2020-05-15 | 上海交通大学 | 人snrpa蛋白在肺癌复发或转移监测中的用途 |
| CN115475247B (zh) * | 2021-06-16 | 2024-02-20 | 厦门大学 | β2-微球蛋白或其抑制剂的制药用途 |
| KR102823777B1 (ko) * | 2021-10-15 | 2025-06-23 | 한국과학기술원 | 인공지능을 이용하여 유전체 염기서열로 질환 진단 및 예측 방법, 그 시스템 |
| CN113921079B (zh) * | 2021-12-06 | 2022-03-18 | 四川省肿瘤医院 | 基于免疫相关基因的msi预测模型构建方法 |
| CN121137146B (zh) * | 2025-07-28 | 2026-04-07 | 首钢医院有限公司 | 检测基因组合物的试剂在制备预测结直肠癌患者远端切缘长度的产品中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2169077A1 (en) * | 2008-09-19 | 2010-03-31 | Vereniging voor christelijk hoger onderwijs, wetenschappelijk onderzoek en patiëntenzorg | Methods and compositions for diagnosing an adenocarcinoma |
| EP2169078A1 (en) | 2008-09-26 | 2010-03-31 | Fundacion Gaiker | Methods and kits for the diagnosis and the staging of colorectal cancer |
| KR101051435B1 (ko) * | 2008-10-22 | 2011-07-22 | 한국생명공학연구원 | 대장암 관련 마커를 이용한 대장암 진단 키트 및 이를 이용한 대장암 진단 방법 |
| KR101073875B1 (ko) | 2008-11-28 | 2011-10-14 | 한국생명공학연구원 | 대장암 진단 마커 및 이를 이용한 대장암 진단방법 |
| SG10201401722XA (en) | 2009-05-01 | 2014-08-28 | Genomic Health Inc | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer andresponse to chemotherapy |
| EP2309002A1 (en) * | 2009-09-29 | 2011-04-13 | Centre National de la Recherche Scientifique (CNRS) | Signature for the diagnosis of colorectal cancer aggressiveness |
| ES2525382T3 (es) * | 2010-03-31 | 2014-12-23 | Sividon Diagnostics Gmbh | Método para la predicción de recurrencia del cáncer de mama bajo tratamiento endocrino |
| EP2426216A1 (en) * | 2010-09-01 | 2012-03-07 | Institut Gustave Roussy (IGR) | Prognostic and/or predictive biomarkers and biological applications thereof |
| CN103403187A (zh) | 2011-01-18 | 2013-11-20 | 艾沃锐斯特基因有限公司 | 结肠直肠癌复发的预后特征 |
| JP2014509189A (ja) | 2011-01-25 | 2014-04-17 | アルマック ダイアグノスティックス リミテッド | 結腸ガン遺伝子発現シグネチャーおよび使用方法 |
| US20150226744A1 (en) * | 2012-09-17 | 2015-08-13 | Ait Austrian Institute Of Technology Gmbh | Colon Cancer Diagnostic Method and Means |
| WO2014085826A2 (en) * | 2012-11-30 | 2014-06-05 | Applied Proteomics, Inc. | Method for evaluation of presence of or risk of colon tumors |
| EP2985296A1 (en) * | 2014-08-13 | 2016-02-17 | Calypso Biotech SA | Antibodies specific for MMP9 |
| PL3743534T3 (pl) | 2018-01-22 | 2022-09-05 | Liquid Biopsy Research LLC | Sposoby wykrywania nowotworu okrężnicy i monitorowania leczenia |
-
2019
- 2019-01-22 PL PL19703616.3T patent/PL3743534T3/pl unknown
- 2019-01-22 AU AU2019209436A patent/AU2019209436B2/en active Active
- 2019-01-22 US US16/253,697 patent/US11414707B2/en active Active
- 2019-01-22 IL IL276089A patent/IL276089B2/en unknown
- 2019-01-22 WO PCT/US2019/014490 patent/WO2019144099A1/en not_active Ceased
- 2019-01-22 EP EP19703616.3A patent/EP3743534B1/en active Active
- 2019-01-22 CN CN201980020784.5A patent/CN112004945B/zh active Active
- 2019-01-22 SG SG11202006974WA patent/SG11202006974WA/en unknown
- 2019-01-22 ES ES19703616T patent/ES2917629T3/es active Active
- 2019-01-22 JP JP2020540396A patent/JP7297770B2/ja active Active
- 2019-01-22 BR BR112020014737-0A patent/BR112020014737A2/pt unknown
- 2019-01-22 KR KR1020207024237A patent/KR20200113237A/ko not_active Ceased
- 2019-01-22 MX MX2020007771A patent/MX2020007771A/es unknown
- 2019-01-22 DK DK19703616.3T patent/DK3743534T3/da active
- 2019-01-22 CA CA3088754A patent/CA3088754A1/en active Pending
-
2022
- 2022-07-26 US US17/815,008 patent/US12305240B2/en active Active
-
2025
- 2025-04-18 US US19/182,871 patent/US20250243553A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2021511057A (ja) | 2021-05-06 |
| EP3743534A1 (en) | 2020-12-02 |
| SG11202006974WA (en) | 2020-08-28 |
| IL276089A (en) | 2020-08-31 |
| IL276089B2 (en) | 2024-07-01 |
| AU2019209436B2 (en) | 2025-06-05 |
| AU2019209436A1 (en) | 2020-08-06 |
| DK3743534T3 (da) | 2022-06-20 |
| CN112004945A (zh) | 2020-11-27 |
| EP3743534B1 (en) | 2022-03-23 |
| KR20200113237A (ko) | 2020-10-06 |
| US20230220482A1 (en) | 2023-07-13 |
| PL3743534T3 (pl) | 2022-09-05 |
| WO2019144099A1 (en) | 2019-07-25 |
| MX2020007771A (es) | 2020-09-03 |
| IL276089B1 (en) | 2024-03-01 |
| US20250243553A1 (en) | 2025-07-31 |
| BR112020014737A2 (pt) | 2020-12-08 |
| JP7297770B2 (ja) | 2023-06-26 |
| US20190226030A1 (en) | 2019-07-25 |
| US11414707B2 (en) | 2022-08-16 |
| ES2917629T3 (es) | 2022-07-11 |
| CN112004945B (zh) | 2025-02-14 |
| US12305240B2 (en) | 2025-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12305240B2 (en) | Methods for colon cancer detection and treatment | |
| US20230298695A1 (en) | Methods for prostate cancer detection and treatment | |
| US20240042069A1 (en) | Predicting peptide receptor radiotherapy using a gene expression assay | |
| HK40042084A (en) | Methods for colon cancer detection and treatment monitoring | |
| HK40042084B (en) | Methods for colon cancer detection and treatment monitoring | |
| HK40043345B (en) | Methods for prostate cancer detection and treatment | |
| HK40043345A (en) | Methods for prostate cancer detection and treatment | |
| HK40035975A (en) | Predicting peptide receptor radiotherapy using a gene expression assay | |
| HK40035975B (en) | Predicting peptide receptor radiotherapy using a gene expression assay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20231127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250113 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250113 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250113 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250206 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250526 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250527 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250723 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250723 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260108 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260108 |